ImpediMed Ltd

ImpediMed operates with a liquidity position of $21.68 million in cash and equivalents, representing 52% of total assets, and a current ratio of 4.86, indicating strong short-term liquidity. The company's price-to-book ratio of 1.39 suggests market valuation is slightly above tangible asset value, while the debt-to-equity ratio of 0.71 reflects a moderate leverage profile. However, negative operating and net income of $23.21 million and $23.24 million, respectively, highlight ongoing profitability challenges. Profitability metrics show significant underperformance relative to industry norms. Return on equity of -113.37% and return on assets of -55.78% indicate severe operational inefficiencies. Gross profit of $10.98 million on $12.72 million in revenue yields a 86.3% gross margin, but this is offset by $23.21 million in operating losses. The company's EBITDA multiple of -0.92x revenue suggests poor cash generation relative to revenue. The company's revenue is concentrated in a single product line (SOZO platform and related applications), with no disclosed geographic diversification in the financial snapshot. This lack of segment or geographic disclosure increases exposure to product-specific risks. The absence of revenue by segment or region in the input data prevents further analysis of concentration risk. Growth trajectory is constrained by negative free cash flow of $19.66 million and capital expenditures of $989,000, indicating ongoing investment in operations without cash generation. Analysts project a mean price target of $0.05, implying 286% upside from the current $0.014 market price, but the company's negative earnings and cash flow raise questions about the sustainability of such projections. Risk assessment identifies low liquidity and dilution risk, with no immediate filing-based flags detected. However, the company's negative operating cash flow of $14.65 million and $23.24 million net loss suggest potential future dilution pressure if capital raising is required. No dilution sources were explicitly identified in the input data. Recent events include the continued commercialization of the SOZO platform and veterinary applications, but no specific filings or transcripts were provided in the input data to detail recent operational or strategic developments.